Altered Expression of Circulating miR-377 and miR-98 in Relapsing-remitting Multiple Sclerosis

2020 ◽  
Author(s):  
Nasrin Hadi ◽  
Faezeh Namazi ◽  
Fatemeh Ketabchi ◽  
Farinaz Khosravian ◽  
Parisa Ravaghi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Mononuclear Cells ◽  
Expression Profiles ◽  
Polymerase Chain Reaction Method ◽  
Peripheral Blood Mononuclear ◽  
Altered Expression ◽  
Mirna Expression Profiles ◽  
Relapsing Remitting ◽  
Polymerase Chain ◽  
Relapsing Remitting Multiple Sclerosis

Background and Aims: Multiple sclerosis (MS) has been assumed to be a Complex and indecipherable disease, and poorly understood with regard to etiology which is characterized by relapses and remissions. The expression of microRNAs (miRNAs) is known to be associated with the regulation of immune responses. Recently, investigations have reported that miRNA expression profiles in blood cells become changed in MS. The aim of this study was to elucidate the alterations in the expression of circulating miR377 and miR-98 in 60 relapsing-remitting MS (RRMS) patients in comparison with controls. Materials and Methods: This study was conducted using a quantitative real-time polymerase chain reaction method to explore the expression of circulating miR-377 and miR-98 in peripheral blood mononuclear cells from 60 RRMS patients, 30 of whom were recurring patients, 30 were two months after relapse patients, and 30 others were controls, in order to examine the association of expression level of these miRNAs with RRMS. Results: Results indicated that the expression of miR-377 significantly increases in recurring patients and two months after relapse patients in comparison with controls (p=0.0017 and p=0.0001, respectively). However, miR-98 demonstrated down regulation in recurring patients and two months after relapse patients (p=0.0002 and p=0.0001, respectively). Conclusions: It can be concluded that miR-377 and miR-98 may be prospective biomarkers with the potential use for diagnosis of RRMS patients in the future investigations.

scholarly journals Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs

2021 ◽  
Vol 11 (8) ◽  
pp. 721
Author(s):  
Afshin Derakhshani ◽  
Zahra Asadzadeh ◽  
Hossein Safarpour ◽  
Patrizia Leone ◽  
Mahdi Abdoli Shadbad ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Mononuclear Cells ◽  
Demyelinating Disease ◽  
Immune Checkpoints ◽  
Peripheral Blood Mononuclear ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Multiple Sclerosis Patients ◽  
Relapsing Remitting Multiple Sclerosis ◽  
The Impact

Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS) that is characterized by inflammation which typically results in significant impairment in most patients. Immune checkpoints act as co-stimulatory and co-inhibitory molecules and play a fundamental role in keeping the equilibrium of the immune system. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) and Programmed death-ligand 1 (PD-L1), as inhibitory immune checkpoints, participate in terminating the development of numerous autoimmune diseases, including MS. We assessed the CTLA-4 and PD-L1 gene expression in the different cell types of peripheral blood mononuclear cells of MS patients using single-cell RNA-seq data. Additionally, this study outlines how CTLA-4 and PD-L1 expression was altered in the PBMC samples of relapsing-remitting multiple sclerosis (RRMS) patients compared to the healthy group. Finally, it investigates the impact of various MS-related treatments in the CTLA-4 and PD-L1 expression to restrain autoreactive T cells and stop the development of MS autoimmunity.

Multiple sclerosis-associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing-remitting multiple sclerosis

2009 ◽  
Vol 15 (4) ◽  
pp. 443-447 ◽  
Author(s):  
M Saresella ◽  
A Rolland ◽  
I Marventano ◽  
R Cavarretta ◽  
D Caputo ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Mononuclear Cells ◽  
Interleukin 10 ◽  
Interferon Γ ◽  
Endogenous Retroviruses ◽  
Peripheral Blood Mononuclear ◽  
Human Endogenous Retroviruses ◽  
Relapsing Remitting ◽  
Factor Α ◽  
Relapsing Remitting Multiple Sclerosis

Background Human endogenous retroviruses are suggested to play a pathogenic role in multiple sclerosis (MS); one of such retroviruses, the MS-associated retroviral agent (MSRV) has repeatedly been isolated in MS patients. Objective and methods We analyzed cytokine profiles in MSRV envelope protein (MSRV ENV-SU)-stimulated peripheral blood mononuclear cells of 30 relapsing-remitting MS patients with either acute (AMS) ( n = 13) or stable (SMS) ( n = 17) disease. Results suggest that MSRV ENV-SU induces the production of inflammatory cytokines, including tumor necrosis factor-α ( P < 0.05) and interferon-γ ( P < 0.004) in AMS patients and of interleukin-10 ( P < 0.05), an inflammation-dampening cytokine, in SMS individuals. Conclusions These data strengthen the hypothesis indicating that MSRV could be involved in the pathogenesis of MS.

No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing—remitting multiple sclerosis patients

2010 ◽  
Vol 16 (3) ◽  
pp. 366-369 ◽  
Author(s):  
R. Reuβ ◽  
V. Schreiber ◽  
A. Klein ◽  
C. Infante-Duarte ◽  
M. Filippi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Peripheral Blood Mononuclear Cells ◽  
Chemokine Receptor ◽  
Peripheral Blood ◽  
Mononuclear Cells ◽  
Intercellular Adhesion ◽  
Peripheral Blood Mononuclear ◽  
Relapsing Remitting ◽  
Blood Mononuclear Cells ◽  
Relapsing Remitting Multiple Sclerosis

We investigated the expression of intercellular adhesion molecules ICAM-1 and ICAM-3 on peripheral blood mononuclear cells in a subgroup of 34 patients with relapsing-remitting multiple sclerosis who were treated orally with the chemokine receptor 1 antagonist BX 471 in a 16-week, randomised, double-blind, placebo-controlled phase II study. ICAM-1 and ICAM-3 expression was measured by flow cytometry at different time points during and after therapy and compared using multivariate analysis of variance and non-parametric Mann Whitney test. ICAM-3 expression on CD14 + peripheral blood mononuclear cells was increased in the verum group under therapy, but did not differ significantly between the verum and placebo groups. Most likely, this trend represents a small epiphenomenon only mediated by receptor cross-talk and feedback mechanisms.

Sign in / Sign up

Export Citation Format

Share Document